|Bid||35.55 x 900|
|Ask||45.00 x 800|
|Day's Range||35.82 - 36.70|
|52 Week Range||7.52 - 40.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 30, 2017 - Jun 2, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.56|
uniQure (QURE) delivered earnings and revenue surprises of 8.06% and -9.39%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Amsterdam-based company said it had a loss of 57 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a ...
~Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061. ~First Patient Successfully Screened into Phase IIb Dose-Confirmation Trial of AMT-061. ~Robert Gut, M.D., Ph.D., Named ...
Gene therapy companies are looking to advance the technology, creating potentially curative treatments for genetic diseases.
Uniqure NV (NASDAQ: QURE ), a gene therapy company that focuses on severe unmet medical needs, could "dominate" the space with its AMT-061 therapy, according to B. Riley FBR. The Analyst B. Riley ...
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has enrolled its first patient in the Phase III HOPE-B pivotal study of AMT-061, an investigational AAV5-based gene therapy incorporating the FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. “We are delighted to have enrolled the first patient in this Phase III pivotal study of a gene therapy for patients with hemophilia B,” said Steve Zelenkofske, D.O., chief medical officer at uniQure.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 13, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Robert Gut, M.D., Ph.D. and David Meek to its Board of Directors. Dr. Gut and Mr. Meek are both seasoned industry experts, each with more than 20 years of biopharma industry experience.
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Willis ...
~Newly Issued Patents in the U.S. and Canada Cover Methods of Treating Hemophilia B and Other Bleeding Disorders using FIX-Padua in AAV Gene Therapy~. ~Additional Issued Patent Covering Manufacturing Further ...
LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on uniQure N.V. (NASDAQ: QURE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=QURE as the Company's latest news hit the wire. On May 18, 2018, the Company announced that it has reported preclinical data in three poster presentations highlighting its expertise in efficient transduction of target cells within affected organs at American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting held in Chicago, Illinois, May 17-18, 2018. The presentations highlighted that uniQure's modular platform is now broadly applicable to treat patients with both liver and central nervous system (CNS) disorders.
--New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5--. --Data Suggest AAV5 Gene Therapies May be Viable Treatments for at Least 97% of Patients--. --Data Presented at the American ...
Uniqure NV (NASDAQ: QURE ) has managed to win the seal of approval from Wells Fargo Securities due to its gene therapy pipeline candidates that target multiple diseases. The Analyst Analyst Jim Birchenough ...
In fact, all three of these shares only show 100% buy ratings and huge upside potential of over 100%. Learn more about retirement planning via TheStreet's newest service. Shares are too cheap right now, argues top Oppenheimer analyst Hartaj Singh.
On a per-share basis, the Amsterdam-based company said it had a loss of 59 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Kensho genetic engineering index has jumped 45% in the past year. It's top components, Uniqure NV, Sangamo Therapeutics and Abeona Therapeutics.